Datopotamab deruxtecan
Phase 2Recruiting 2 views this week 0 watching⚡ Active
Interest: 42/100
42
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Breast Cancer Stage IV
Conditions
Breast Cancer Stage IV
Trial Timeline
Jul 1, 2023 → May 23, 2026
NCT ID
NCT05866432About Datopotamab deruxtecan
Datopotamab deruxtecan is a phase 2 stage product being developed by Daiichi Sankyo for Breast Cancer Stage IV. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05866432. Target conditions include Breast Cancer Stage IV.
What happened to similar drugs?
20 of 20 similar drugs in Breast Cancer Stage IV were approved
Approved (20) Terminated (4) Active (0)
Hype Score Breakdown
Clinical
12
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06279728 | Pre-clinical | Completed |
| NCT06676917 | Phase 2 | Withdrawn |
| NCT06176261 | Phase 2 | Recruiting |
| NCT05866432 | Phase 2 | Recruiting |
Competing Products
20 competing products in Breast Cancer Stage IV